AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27113085 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 452
Study 25558265 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth training workshop
Number of subjects: 180
Study 25558265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 22779215 — intervention group
Group type: EXPERIMENTAL
Intervention: New dentifrice containing 8.0% arginine, calcium carbonate, and 1000 ppm sodium monofluorophosphate (MFP)
Number of subjects: 0
Study 22779215 — intervention group
Group type: COMPARATOR
Intervention: Commercially available dentifrice containing 1000 ppm sodium monofluorophosphate (MFP)
Number of subjects: 0
Study 20869710 — intervention group
Group type: EXPERIMENTAL
Intervention: EPBD for 5 minutes (n = 84)
Number of subjects: 170
Study 20869710 — intervention group
Group type: COMPARATOR
Intervention: EPBD for 1 minute (n = 86)
Number of subjects: 170
Study 17892635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch containing rivastigmine (Exelon)
Number of subjects: 0
Study 17892635 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of AD therapies
Number of subjects: 0
Study 16359213 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 220
Study 12043315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (24 patients, 15 men and 9 women, average age 42.3 years)
Number of subjects: 70
Study 12043315 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (24 patients, 18 men and 6 women, average age 43.2 years)
Number of subjects: 70
Study 12043315 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (22 patients, 18 men and 4 women, average age 42.9 years)
Number of subjects: 70
Study 10543267 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg albendazole daily in three cycles of 6 weeks with 2 weeks between cycles
Number of subjects: 20
Study 10543267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8544113 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 24
Study 8544113 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence condition
Number of subjects: 24
Study 8544113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1977780 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 15
Study 1977780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 15
Study 1977780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 897573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C daily (pilot study)
Number of subjects: 814
Study 897573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C daily (main study)
Number of subjects: 814
Study 897573 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 814
Study 31013363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol 600 mg daily for 12 weeks
Number of subjects: 50
Study 31013363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 50
Study 31013363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol
Number of subjects: 50
Study 31013363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31013363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol and Placebo
Number of subjects: 50
Study 28524039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gubiao Pixie prescription (Radix Astragali 30 g, Bran fried Rhizoma Atracylodis 20 g, Raidix Saposhnikoviae 12 g, Radix Scutellariae 10 g, Fructus Tsaoko 6 g), taken in warm water 300 mL, twice a day after meals for 10 days.
Number of subjects: 100
Study 28524039 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without special intervention (Control group).
Number of subjects: 100
Study 28524039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gubiao Pixie prescription (experimental group).
Number of subjects: 100
Study 25732251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap (∼90min)
Number of subjects: 0
Study 25732251 — intervention group
Group type: COMPARATOR
Intervention: Control (watched DVDs)
Number of subjects: 0
Study 25732251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nap and Control)
Number of subjects: 0
Study 23538158 — intervention group
Group type: EXPERIMENTAL
Intervention: Early infarct-related artery (IRA) patency (TIMI 2 or 3 flow)
Number of subjects: 3093
Study 23538158 — intervention group
Group type: COMPARATOR
Intervention: No early IRA patency (TIMI 0 or 1 flow)
Number of subjects: 3093
Study 22045968 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT plus PCI
Number of subjects: 489
Study 22045968 — intervention group
Group type: COMPARATOR
Intervention: OMT only
Number of subjects: 489
Study 22045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 489
Study 19705035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurexan
Number of subjects: 826
Study 19705035 — intervention group
Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 826
Study 17079851 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated vitamin D3
Number of subjects: 0
Study 17079851 — intervention group
Group type: COMPARATOR
Intervention: Plain vitamin D
Number of subjects: 0
Study 17079851 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonate
Number of subjects: 0
Study 15307012 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (indinavir + zidovudine or stavudine + lamivudine)
Number of subjects: 1156
Study 15307012 — intervention group
Group type: COMPARATOR
Intervention: Dual-drug therapy (zidovudine or stavudine + lamivudine)
Number of subjects: 1156
Study 11397621 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime (3 g/day)
Number of subjects: 35
Study 11397621 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ceftazidime (2 g every 8 h)
Number of subjects: 35
Study 9425681 — intervention group
Group type: EXPERIMENTAL
Intervention: Word frequency effects on lexical decision task (LDT) at 75% accuracy level.
Number of subjects: 0
Study 9425681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental lexica of participants with very-low-frequency words.
Number of subjects: 0
Study 7506324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimakalim (0.25-1 mg)
Number of subjects: 12
Study 7506324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3329967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fioricet
Number of subjects: 198
Study 3329967 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 198
Study 3329967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 29533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-bridge technique augmented with 3D collagen
Number of subjects: 112
Study 29533674 — intervention group
Group type: COMPARATOR
Intervention: Suture-bridge technique
Number of subjects: 112
Study 27441910 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) consisting of 8 weekly cycles of cetuximab, carboplatin, and paclitaxel followed by CRT
Number of subjects: 118
Study 27441910 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (CRT)
Number of subjects: 118
Study 24681859 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital aural atresia (CAA)
Number of subjects: 35
Study 24681859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorineural hearing loss (SNHL)
Number of subjects: 35
Study 24681859 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 23587875 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% and dexamethasone 10 mg (RD)
Number of subjects: 150
Study 23587875 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% with i.v. dexamethasone 10 mg (RDiv)
Number of subjects: 150
Study 23587875 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.5% (R)
Number of subjects: 150
Study 20645666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy utilization algorithm
Number of subjects: 100
Study 20645666 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy utilization
Number of subjects: 100
Study 20645666 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm identification
Number of subjects: 100
Study 19278082 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate® Total® dentifrice
Number of subjects: 28
Study 19278082 — intervention group
Group type: COMPARATOR
Intervention: Colgate® Cavity Protection dentifrice
Number of subjects: 28
Study 15948697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% cimetidine rinse
Number of subjects: 37
Study 15948697 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 37
Study 12891954 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous terbutaline infusion (SQ group)
Number of subjects: 558
Study 12891954 — intervention group
Group type: COMPARATOR
Intervention: Oral tocolytics (PO group)
Number of subjects: 558
Study 12891954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall costs for SQ group
Number of subjects: 558
Study 10999085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (0,1,2 schedule)
Number of subjects: 117
Study 10999085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (0,1,2,6 schedule)
Number of subjects: 117
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume aspiration
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum albumin (< 30 mg/dl)
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude mortality rate
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia-related mortality
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributable mortality
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior swallowing disorders
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature on admission < 37 degrees C
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory frequency > 30/min
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more affected lobes on chest radiograph
Number of subjects: 101
Study 8912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 101
Study 1991422 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision, drainage and fistulectomy with primary partial internal sphincterectomy (group I)
Number of subjects: 70
Study 1991422 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage alone (group II)
Number of subjects: 70
Study 6408298 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.25 clinical units/kg bw/h)
Number of subjects: 30
Study 6408298 — intervention group
Group type: COMPARATOR
Intervention: Synthetic somatostatin (250 micrograms/h)
Number of subjects: 30
Study 31937248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (measured by Face Pain Scale, FPS, range 0-6) in the older group (65-79 years)
Number of subjects: 772
Study 31937248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (measured by Face Pain Scale, FPS, range 0-6) in the oldest-old group (80 years or older)
Number of subjects: 772
Study 31937248 — intervention group
Group type: COMPARATOR
Intervention: Recurrent falls in the older group (65-79 years)
Number of subjects: 772
Study 31937248 — intervention group
Group type: COMPARATOR
Intervention: Recurrent falls in the oldest-old group (80 years or older)
Number of subjects: 772
Study 27701370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of iloprost (Endoprost®) after balloon angioplasty of below-the-knee vessels
Number of subjects: 32
Study 26783035 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles injection around the primary tumor
Number of subjects: 114
Study 26783035 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 114
Study 26934294 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE-Q appearance scales measuring skin, lips, and facial rhytids (overall, forehead, glabella, lateral periorbital area, lips, marionette lines)
Number of subjects: 783
Study 26934294 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE-Q adverse effects checklists for problems after skin and lip treatment
Number of subjects: 783
Study 26934294 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment scores on 7 of the 8 appearance scales
Number of subjects: 783
Study 24251724 — intervention group
Group type: EXPERIMENTAL
Intervention: Written pain neuroscience education
Number of subjects: 114
Study 24251724 — intervention group
Group type: COMPARATOR
Intervention: Written relaxation training
Number of subjects: 114
Study 23010601 — intervention group
Group type: EXPERIMENTAL
Intervention: SII RMab 10 IU/kg
Number of subjects: 0
Study 23010601 — intervention group
Group type: COMPARATOR
Intervention: HRIG 20 IU/kg
Number of subjects: 0
Study 19276403 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive, individualized cognitive/sensorimotor stimulation by public health nurses
Number of subjects: 62
Study 19276403 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 62
Study 18226292 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet (38 % fat, 22 % MUFA)
Number of subjects: 20
Study 18226292 — intervention group
Group type: COMPARATOR
Intervention: SFA-enriched diet (38 % fat, 20 % SFA)
Number of subjects: 20
Study 18226292 — intervention group
Group type: COMPARATOR
Intervention: CHO-rich diet (30 % fat, < 10 % SFA, 55 % CHO)
Number of subjects: 20
Study 18226292 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet
Number of subjects: 20
Study 15298982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour submaximal aerobic exercise
Number of subjects: 16
Study 15298982 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese skeletal muscle
Number of subjects: 16
Study 15298982 — intervention group
Group type: COMPARATOR
Intervention: Lean skeletal muscle
Number of subjects: 16
Study 15298982 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake
Number of subjects: 16
Study 15298982 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of body fat and maximal oxygen uptake per kilogram of fat-free mass
Number of subjects: 16
Study 12404672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 37
Study 12404672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10204636 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 10204636 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 10204636 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0
Study 10204636 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7753268 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membrane dialysis
Number of subjects: 26
Study 7753268 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membrane dialysis
Number of subjects: 26
Study 2278333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pulse oximetry
Number of subjects: 10
Study 2278333 — intervention group
Group type: COMPARATOR
Intervention: Finger pulse oximetry
Number of subjects: 10
Study 6938018 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral therapy with estramustine phosphate (Estracyt)
Number of subjects: 0
Study 6938018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral therapy with estramustine phosphate (Estracyt)
Number of subjects: 0
Study 30616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral sedation (hydroxyzine, lorazepam, melatonin)
Number of subjects: 348
Study 30616675 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation (midazolam, propofol)
Number of subjects: 348
Study 30616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral sedation
Number of subjects: 348
Study 30616675 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 348
Study 27847368 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated cholera vaccine CVD 103-HgR (Vaxchora)
Number of subjects: 0
Study 27847368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26352257 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed OSS (on-site support) after training
Number of subjects: 36
Study 26352257 — intervention group
Group type: COMPARATOR
Intervention: Immediate OSS (on-site support) after training
Number of subjects: 36
Study 26352257 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended OSS (three additional visits over six months)
Number of subjects: 36
Study 23835735 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program (CHRP)
Number of subjects: 0
Study 21157384 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg · kg(‐1))
Number of subjects: 13
Study 21157384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 21157384 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and Placebo
Number of subjects: 13
Study 20031767 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1468
Study 20031767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1468
Study 17142256 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotapes of conversations with a neonatologist (n=102)
Number of subjects: 200
Study 17142256 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=98)
Number of subjects: 200
Study 14987586 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 14987586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11320916 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpable short saphenous vein (SSV) assessment
Number of subjects: 160
Study 11320916 — intervention group
Group type: COMPARATOR
Intervention: Not palpable short saphenous vein (SSV) assessment
Number of subjects: 160
Study 11320916 — intervention group
Group type: COMPARATOR
Intervention: Hand-held Doppler insonation (HHD)
Number of subjects: 160
Study 11320916 — intervention group
Group type: COMPARATOR
Intervention: Combined tests (palpation and HHD)
Number of subjects: 160
Study 9562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at 60% of peak oxygen uptake (Vo2) three times a week for 10 weeks (Group T)
Number of subjects: 71
Study 9562003 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Group C did not exercise)
Number of subjects: 71
Study 9562003 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 71
Study 9562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hibernating myocardium assessed by LDSE
Number of subjects: 71
Study 9562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐to‐posttraining difference in LVEF at peak dobutamine infusion
Number of subjects: 71
Study 9562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a viable response at baseline
Number of subjects: 71
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate-enriched diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleate-enriched diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Buoyant LDL from all subjects
Number of subjects: 0
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense LDL from linoleate group
Number of subjects: 0
Study 8148354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense LDL from oleate diet group
Number of subjects: 0
Study 3130259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g calcium added daily for 6‐7 weeks
Number of subjects: 14
Study 3130259 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 14
Study 3130259 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium loading
Number of subjects: 14
Study 31383436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and Emotional Intelligence Program (PINEP) - 12 sessions lasting an hour and a half
Number of subjects: 89
Study 31383436 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 89
Study 27784415 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP (System One RemStar Auto A-Flex)
Number of subjects: 61
Study 27784415 — intervention group
Group type: COMPARATOR
Intervention: CPAP (manually titrated, fixed pressure)
Number of subjects: 61
Study 25835443 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervation
Number of subjects: 361
Study 25835443 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (non-crossover)
Number of subjects: 361
Study 25835443 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (crossover)
Number of subjects: 361
Study 23131594 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocavitary brachytherapy (EBT) boost for T1,2N+ tumors
Number of subjects: 411
Study 23131594 — intervention group
Group type: EXPERIMENTAL
Intervention: EBT or stereotactic radiation boost for T3,4 tumors
Number of subjects: 411
Study 21238531 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser at 8.5J/cm(2) energy density
Number of subjects: 51
Study 21238531 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.25W, 20Hz, 0% water, 10% air
Number of subjects: 51
Study 21238531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 18447210 — intervention group
Group type: EXPERIMENTAL
Intervention: Head penetration needling group
Number of subjects: 71